Earnings call transcript: Cera Sanitaryware’s Q4 2026 shows recovery By Investing.com

Cera Sanitaryware posted Q4 FY26 revenue of INR 644 crore, up 11.4% YoY, with growth driven mainly by 12% volume expansion and a better product mix, though EBITDA margin fell 310 bps to 15.2% due to brass/input-cost inflation and trade discounts. Management guided to FY27 revenue growth of 18%-20% and EBITDA margins of 14%-15%, supported by price hikes, improving retail demand, and brand expansion at Senator and Polipluz. Shares rose 5.97% after the results, while cash and equivalents remained strong at INR 853 crore.

Analysis

The key second-order read is that CERA is using a supply shock to reprice the channel, not just defend margins. If Morbi disruption persists into Q1–Q2, the company should gain disproportionate shelf space and project share because it has inventory, sourcing flexibility, and internalized capacity while weaker regional suppliers face intermittent outages; that creates a near-term volume tailwind that can offset some discounting pressure. The market is likely underestimating how much this can shift mix toward CERA’s own brands and away from outsourced SKUs, improving control over gross margin over the next 2 quarters.

The bigger strategic implication is that brand-building spend is now becoming a deliberate option on operating leverage. Senator/Polipluz are still small enough that their losses won’t matter at the group level, but the current investment phase establishes a low-base embedded call on FY27/FY28 growth if distribution targets are hit; the risk is that management overextends marketing before the pricing reset fully flows through in projects. Because project pricing lags retail by several months, earnings quality should improve mechanically into H2 if brass stabilizes and discount intensity normalizes.

Consensus is probably too focused on the headline margin compression and not enough on free cash flow durability. With a very large cash balance and limited near-term capex burden, downside is cushioned even if FY27 margin recovery is slower than guided, which reduces balance-sheet risk versus peers using more leverage to defend share. The main contrarian risk is that this looks like a temporary share gain unless the company converts it into permanent channel wins; if gas and brass ease sharply, the supply advantage fades and the current re-rating could stall.

Key Decisions for Investors

• Go long CERA on pullbacks over the next 2-6 weeks; thesis is a Q1/Q2 volume + pricing inflection from supply disruption, with 10-15% upside if margins hold near the guided band and a tighter downside because of cash-rich balance sheet.
• Pair trade: long CERA / short a leveraged regional building-materials or sanitaryware proxy with higher outsourcing dependence for 1-3 months; the trade benefits if Morbi disruption persists and outsourced competitors miss volumes.
• Sell downside protection on CERA only after the next quarterly update confirms discount normalization; until then, implied vol likely underprices a supply-driven earnings beat in H1 FY27.
• If available in the listed universe, prefer CERA over more levered discretionary-home names for the next 2 quarters; CERA has a cleaner FCF cushion and better ability to pass through input costs without liquidity stress.
• Take profits into strength if the stock re-rates to a full multi-quarter margin recovery before evidence of project price pass-through; the risk/reward worsens if the market prices FY27 growth before the brand investments prove ROI.